Long-term running data not associated with arthritis risk: The marathon study

Published Date: 17 Mar 2023

A group of researchers from the annual meeting of the American Academy of Orthopedic Surgeons (AAOS) "analyzed the data and...

Read Full News

Latest News



Todays Updates


Interpreting the DAWN Trial: Where Anti-CD38 Therapy May Fit in NMOSD Care Marco Meglio


Neurologists Michael Levy, MD, PhD, and Fu-Dong Shi, MD, PhD, discuss the rationale, design, and clinical implications of the phase 3 DAWN trial evaluating daratumumab in aquaporin-4–positive NMOSD.

ISC 2026 Stroke Updates: Extended Time Windows and Secondary Prevention Strategies Ava L. Liberman, MD, Isabella Ciccone, MPH


Ava L. Liberman, MD, assistant professor of clinical neurology at Weill Cornell Medicine, shared key takeaways from stroke data presented at the 2026 International Stroke Conference.

American College of Physicians Policy Paper Recommends Retiring 'Provider' Term for Physicians Isabella Ciccone, MPH


ACP urged to drop “provider” for physicians, warning it blurs expertise, commodifies care, and erodes professional identity, trust, and the patient relationship.

CD-38 Monoclonal Antibody Daratumumab Shows Promise as Treatment for NMOSD in Phase 3 DAWN Study Marco Meglio


Phase 3 DAWN data show daratumumab cuts NMOSD relapse risk 76%, stays well tolerated, and may improve disability, signaling a new targeted option.

Tips on Billing Issues in Dermatology Practices, With Daniel Siegel, MD Daniel M. Siegel, MD


Siegel addressed additional points presented in his Maui Derm 2026 session, 'How To Maximize Your Billing Effectiveness in the Era of Dwindling Reimbursements and ICD-10.'

7 Pulmonology Headlines You Missed in January 2026


7 Pulmonology Headlines You Missed in January 2026

Todays Updates


Interpreting the DAWN Trial: Where Anti-CD38 Therapy May Fit in NMOSD Care Marco Meglio


Neurologists Michael Levy, MD, PhD, and Fu-Dong Shi, MD, PhD, discuss the rationale, design, and clinical implications of the phase 3 DAWN trial evaluating daratumumab in aquaporin-4–positive NMOSD.

ISC 2026 Stroke Updates: Extended Time Windows and Secondary Prevention Strategies Ava L. Liberman, MD, Isabella Ciccone, MPH


Ava L. Liberman, MD, assistant professor of clinical neurology at Weill Cornell Medicine, shared key takeaways from stroke data presented at the 2026 International Stroke Conference.

American College of Physicians Policy Paper Recommends Retiring 'Provider' Term for Physicians Isabella Ciccone, MPH


ACP urged to drop “provider” for physicians, warning it blurs expertise, commodifies care, and erodes professional identity, trust, and the patient relationship.

CD-38 Monoclonal Antibody Daratumumab Shows Promise as Treatment for NMOSD in Phase 3 DAWN Study Marco Meglio


Phase 3 DAWN data show daratumumab cuts NMOSD relapse risk 76%, stays well tolerated, and may improve disability, signaling a new targeted option.

Tips on Billing Issues in Dermatology Practices, With Daniel Siegel, MD Daniel M. Siegel, MD


Siegel addressed additional points presented in his Maui Derm 2026 session, 'How To Maximize Your Billing Effectiveness in the Era of Dwindling Reimbursements and ICD-10.'

7 Pulmonology Headlines You Missed in January 2026


7 Pulmonology Headlines You Missed in January 2026

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Radiation therapy can promote amphiregulin, which increases growth of metastases

2.

The FDA approves Enhertu for HER2-positive cancers, regardless of tumor type.

3.

A new theranostic drug targets different cancer types.

4.

Did U.S. Government Play a Role in Remote Tribe's Widespread Illness and Cancer?

5.

Study indicates that exercise can help colon cancer survivors live as long as matched individuals


© Copyright 2025 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot